

Regional bulletin for the availability of antimalarial medicines: Third Quarter 2014

Volume 3 Number 1
2014



Plataforma Regional sobre
Acceso e Innovación para
Tecnologías Sanitarias
PRAIS

www.paho.org/prais

This bulletin is developed through a collaborative effort between the National Malaria Control Programs of the Region of the Americas, PAHO/WHO and SIAPS/USAID to facilitate sharing of information between countries in the Americas. The objectives of the bulletin are to increase awareness of stocks of antimalarial medicine, generate stock out alerts and promote exchanges and donations of antimalarial medicines between countries.

This bulletin is based on information provided by countries in South and Central America who participate in the Amazon Malaria Initiative (AMI) and are members of the Amazon Network for the Surveillance of Antimalarial Drug Resistance (RAVREDA). The bulletin offers information on the availability of medicines in central and regional medical stores that allow countries' decision makers to assure uninterrupted supply.

The following tables detail the availability of antimalarial medicines for each country. Stock out is considered zero availability in the storerooms.

The indicator of months of availability is calculated by each country by dividing the availability of medicines by the average monthly consumption or distribution. The average consumption is found by dividing the distribution or consumption over the previous year by 12.

This third bulletin includes information from nine countries, four from South America and five from Central America. Eight countries sent central and regional level data.



Availability of medicines for the third quarter, 2014

Medications			BELIZE					BRAZIL					COLOMBIA				
			Central			Department		Central			Department		Central			Department	
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/ consumption	Units of medications available	Months of availability according to distribution/ consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet					1	750	0.48			1	0	0.00	2,268	4.45	
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet					1	2,190	1.06			1	0	0.00	9,720	2.74	
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet					1	1,320	0.60			1	306	0.04	42,786	5.83	
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	5.00	0.00	0.00	0.00	1	23,850	5.61			1	2,040	0.04	172,176	3.73
	005	Artesunate 50 mg tablet															
	006	Artesunate 100 mg tablet															
	007	Artesunate 250 mg tablet															
	008	Artesunate+ SP (Children)															
	009	Artesunate+ SP (Adolescent)															
	010	Artesunate+ SP (Adults)															
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.						1	440	9.78							
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.						1	440	9.17							
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.						1	440	5.24							
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.						1	300	3.80							
	015	Mefloquine 250 mg tablet	0	700	14.00	60	6.00										
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet															
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	69,000	6.90	13,500	2.93	1	2,810,500	10.20			1	911,530	13.69	387,432	6.53
	018	Chloroquine phosphate 100 mg tablet	0	12,000													
	019	Primaquine phosphate 5 mg tablet	1	0	0.00	0	0.00	1	648,500	5.04			1	215,645	11.6	277,892	17.82
	020	Primaquine phosphate 7.5 mg tablet															
	021	Primaquine phosphate 15 mg tablet	1	1,000	14.29	5,340	76.29	1	3,699,500	11.24			1	33,510	0.61	87,735	1.14
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules						1	20,104	22.61							
	023	Artesunate rectal 50 mg										1	2,970	9.28	2,874	5.53	
	024	Artesunate rectal 100 mg															
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule						1	37,015	19.42			1	634	3.32	1,076	2.30
	026	Clindamycin Hydrochloride 300 mg Capsule						1	0	0.00							
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable						1	0	0.00							
	028	Clindamycin Hydrochloride 150 mg Capsule															
	029	Clindamycin 75mg/5mL suspension															
	030	Doxycycline 100 mg Capsule						1	10,425	0.77							
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable	0	100				1	60,800	60.80			1	1,502	5.01	2,252	2.38
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable															
033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable																
034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable																
035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable																
036	Quinine Sulfate 300mg tablet	0	200									1	57,570	22.42	10,183	6.06	
037	Quinine Sulfate 500 mg tablet						1	81,000	10.60								

Source: Consolidated National Report from Countries

Availability of medicines for the third quarter, 2014

Medications			ECUADOR					GUATEMALA					HONDURAS				
			Central			Department		Central			Department		Central			Department	
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet	1	147	109.57	74	55.16										
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet	1	236	175.90	258	192.30										
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet	1	107	79.75	338	251.93										
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet	1	77	5.74	202	15.06										
	005	Artesunate 50 mg tablet															
	006	Artesunate 100 mg tablet															
	007	Artesunate 250 mg tablet															
	008	Artesunate+ SP (Children)															
	009	Artesunate+ SP (Adolescent)															
	010	Artesunate+ SP (Adults)															
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.															
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.															
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.															
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.															
	015	Mefloquine 250 mg tablet															
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet										1	0	0.00	0	0.00	
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	28,245	156.19	11,180	61.82	1	0	0.00	69,840	3.27	1	806,027	4.69	161,701	6.39
	018	Chloroquine phosphate 100 mg tablet															
	019	Primaquine phosphate 5 mg tablet						1	0	0.0	161,202	10.94	1	532,840	6.42	52,020	3.33
	020	Primaquine phosphate 7.5 mg tablet	1	0	0.00	2,794	110.36										
	021	Primaquine phosphate 15 mg tablet	1	1,926	7.61	16,622	65.66	1	0	0.00	113,249	4.12	1	338,070	3.57	42,406	2.43
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules															
	023	Artesunate rectal 50 mg															
	024	Artesunate rectal 100 mg															
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule	1	7	0.52	126	9.39										
	026	Clindamycin Hydrochloride 300 mg Capsule	1	1,266	94.36	218	16.25										
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable															
	028	Clindamycin Hydrochloride 150 mg Capsule															
	029	Clindamycin 75mg/5mL suspension															
	030	Doxycycline 100 mg Capsule															
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable															
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable															
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable															
	034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable										1	81	13.50	0	0.00	
	035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable															
	036	Quinine Sulfate 300mg tablet	1	169	3.00	3,613	64.12					1	0	0.00	0	0.00	
	037	Quinine Sulfate 500 mg tablet															

Source: Consolidated National Report from Countries

Availability of medicines for the third quarter, 2014

Medications			NICARAGUA				PANAMA					PERU					
			Central			Department		Central			Department		Central			Department	
			Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption	Obligatory medication based on the Standard Treatment Guidelines (1=yes ; 0=no)	Units of medications available	Months of availability according to distribution/consumption	Units of medications available	Months of availability according to distribution/consumption
P. falciparum treatments	001	Artemether-Lumefantrine 20/120 mg X 6 tablet					1	180	7.50	0	0.00						
	002	Artemether-Lumefantrine 20/120 mg X 12 tablet					1	360	15.00	0	0.00						
	003	Artemether-Lumefantrine 20/120 mg X 18 tablet					1	540	22.50	0	0.00						
	004	Artemether-Lumefantrine 20/120 mg X 24 tablet					1	720	30.00	710	29.58						
	005	Artesunate 50 mg tablet										1	151,338.00	455.84	42,137	64.23	
	006	Artesunate 100 mg tablet															
	007	Artesunate 250 mg tablet										1	16,998	17.12	25,687	13.09	
	008	Artesunate+ SP (Children)															
	009	Artesunate+ SP (Adolescent)															
	010	Artesunate+ SP (Adults)															
	011	Artesunate-Mefloquine 25/55 mg x 3 tablet.															
	012	Artesunate-Mefloquine 25/55 mg x 6 tablet.															
	013	Artesunate-Mefloquine 100/220 mg x 3 tablet.															
	014	Artesunate+Mefloquine 100/220 mg x 6 tablet.															
	015	Mefloquine 250 mg tablet										1	0	0.00	1,260	0.32	
	016	Sulfadoxine-Pyrimethamine 25/500mg tablet						0	9,000								
P. vivax treatments	017	Chloroquine phosphate 150 mg tablet	1	1,584,020	7.21	964,841	4.08	1	141,000	2.47	34,510	16.01	1	309,600	13.43	551,001	16.28
	018	Chloroquine phosphate 100 mg tablet															
	019	Primaquine phosphate 5 mg tablet	1	418,003	3.48	374,758	2.92	1	15,000	3.00	0	0.00					
	020	Primaquine phosphate 7.5 mg tablet											1	0	0.00	0	0.00
	021	Primaquine phosphate 15 mg tablet	1	540,965	5.11	493,472	3.93	1	369,000	12.72	52,620	15.03	1	191,520	5.93	126,827	2.68
Severe and Special Case malaria treatments	022	Artemether 80 mg/1 ml, 1 ml ampoules											0	24			
	023	Artesunate rectal 50 mg															
	024	Artesunate rectal 100 mg															
	025	Artesunate sodium bicarbonate 60 mg/1 ml ampoule															
	026	Clindamycin Hydrochloride 300 mg Capsule	1	1,206,040	12.03	241,929	1.98										
	027	Clindamycin Phosphate 150 mg/ mL x 4 mL injectable															
	028	Clindamycin Hydrochloride 150 mg Capsule															
	029	Clindamycin 75mg/5mL suspension															
	030	Doxycycline 100 mg Capsule															
	031	Quinine Hydrochloride 300 mg/ mL x 2 mL injectable	1	1,163	10.29	579	4.11										
	032	Quinine Hydrochloride 600 mg/ mL x 2 mL injectable															
	033	Quinine Dihydrochloride 125 mg/ mL x 4 mL injectable															
	034	Quinine Dihydrochloride 300 mg/ mL x 2 mL injectable											1	10,706	194.65	0	0.00
	035	Quinine Dihydrochloride 600mg/ml x 2 mL injectable															
	036	Quinine Sulfate 300mg tablet											1	1,000	5.35	207	0.56
	037	Quinine Sulfate 500 mg tablet															

Source: Consolidated National Report from Countries

Indicators reported for the third quarter, 2014

INDICATORS	Belize		Brasil		Colombia		Ecuador		Guatemala		Honduras		Nicaragua		Panama		Peru	
	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart	Central	Depart
No. of department warehouses that report medication availability data.		7				31		9		25		13		19		14		33
% of regional stores that report stockout in one or more antimalarials required by the Standard Treatment Guidelines (STG).		100%				56%		82%		44%		100%		16%		7%		93%
Number of medicines required in the Standard Treatment Guidelines (STG)	4	4	18		11	11	10	10	3	3	6	6	5	5	7	7	8	8
Number of STG medicines that are available.	3	2	16		9	11	9	10	0	3	4	3	5	5	7	3	6	6
% of STG medications available	75%	50%	89%		82%	100%	90%	100%	0%	100%	67%	50%	100%	100%	100%	43%	75%	75%
% of STG medications not available	25%	50%	11%		18%	0%	10%	0%	100%	0%	33%	50%	0%	0%	0%	57%	25%	25%
% of STG medications with availability less than the minimum security stock (3 months)	50%	75%	33%		45%	36%	30%	0%	100%	0%	33%	67%	0%	40%	29%	57%	25%	63%
% of STG medications which are overstocked (more than 24 months of availability)	0%	25%	6%		0%	0%	50%	70%	0%	0%	0%	0%	0%	0%	14%	14%	25%	13%

This bulletin was elaborated within the framework of AMI/RAVREDA with assistance from PAHO/WHO, specifically the Medicines and Health Technologies (HSS/MT) unit and the Regional Malaria Program (CHA/VT) and the USAID funded program Systems for Improved Access to Pharmaceuticals and Services (SIAPS). Data for the report was sent by the National Malaria Control Programs of the participating countries. The consolidation and editing of the bulletin was completed by the regional team of the PAHO/WHO Strategic Fund, which utilized the previous format developed by DIGEMID and SIAPS/USAID as a reference



USAID
FROM THE AMERICAN PEOPLE

SIAPS
Systems for Improved Access
to Pharmaceuticals and Services